BIGBEAR
PHARMACEUTICAL
Alpelisib is an oral phosphatidylinositol-3-kinase (PI3K) inhibitor. Its mechanism of action is to block the activity of PI3K enzymes, inhibit the proliferation and spread of tumor cells, and simultaneously induce the apoptosis of breast cancer cells.
AuthenticGuaranteeFast DeliveryPrivacy Mechanism of Action of Alpelisib1. Selective inhibition of the phosphatidylinositol-3-kinase alpha isoform (PI3Kα). Mutations in the gene encoding PI3···【More】
Update: 31 Jul,2026Source: BigbearViews: 110
Alpelisib Specific Drug Interactions1. Bisphosphonates (e.g., alendronate, ibandronate, risedronate, zoledronic acid): May increase the risk of osteon···【More】
Update: 31 Jul,2026Source: BigbearViews: 111
Alpelisib Special Considerations for Specific Populations1. PregnancyMay cause fetal harm.2. LactationIt is unknown whether alpelisib is excreted into···【More】
Update: 31 Jul,2026Source: BigbearViews: 124
Alpelisib is an antineoplastic agent that selectively inhibits the phosphatidylinositol 3-kinase alpha isoform (PI3Kα).Alpelisib ContraindicationsHist···【More】
Update: 31 Jul,2026Source: BigbearViews: 108
Alpelisib may cause various side effects during treatment. If you do not know much about the side effects of alpelisib, please consult your doctor pro···【More】
Update: 30 Jul,2026Source: BigbearViews: 131
Alpelisib ContraindicationsHypersensitivity to the active substance or to any of the excipients is contraindicated.Alpelisib Age Restrictions1. Breast···【More】
Update: 29 Jul,2026Source: BigbearViews: 112
Dose Adjustments for Adverse Reactions in the Treatment of PIK3CA-Related Overgrowth Spectrum1. Recommended Dose Reduction in Adult Patients(1) First ···【More】
Update: 29 Jul,2026Source: BigbearViews: 119
Alpelisib Dose Adjustments in Special Populations1. Renal Impairment Adjustments(1) Mild to moderate renal impairment: No dose adjustment required.(2)···【More】
Update: 29 Jul,2026Source: BigbearViews: 114
Alpelisib dosage and administration depend on the disease being treated and the patient's age; specific use should be consulted with a physician. ···【More】
Update: 29 Jul,2026Source: BigbearViews: 113
Alpelisib was approved by the U.S. Food and Drug Administration (FDA) in 2019 for use in combination with fulvestrant to treat hormone receptor-positi···【More】
Update: 23 Mar,2026Source: BigbearViews: 167
Alpelisib has been approved for marketing in several countries and regions, including the United States, the European Union, and Japan, but it has not···【More】
Update: 23 Mar,2026Source: BigbearViews: 186
Alpelisib, an oral small-molecule PI3Kα inhibitor from Novartis, Switzerland, offers new hope for patients with advanced or metastatic breast cancer c···【More】
Update: 23 Mar,2026Source: BigbearViews: 173
Alpelisib has relatively many adverse reactions. If not detected and treated promptly and correctly, these can have a significant impact on the patien···【More】
Update: 23 Mar,2026Source: BigbearViews: 181
Efficacy and Actions of ElacestrantElacestrant is an anti-tumor drug, belonging to the estrogen receptor antagonist class.Efficacy and Actions of Elac···【More】
Update: 18 Mar,2026Source: BigbearViews: 155
Precautions for Axitinib UseAxitinib is an oral, highly selective tyrosine kinase inhibitor developed by Pfizer, primarily used to treat advanced rena···【More】
Update: 18 Mar,2026Source: BigbearViews: 152
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
